WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase II/III pivotal trial of its potential first-in-class vascular disrupting agent, ZYBRESTAT™ (combretastatin-A4 phosphate / CA4P) in anaplastic thyroid cancer (ATC). The FDA’s agreement to the SPA means that, if OXiGENE follows the agreed-upon protocol, the results of the trial support the safety and effectiveness of ZYBRESTAT, and no substantive scientific issues are identified after the trial begins, much of the uncertainty associated with the design of a pivotal clinical trial should be removed.
